Ríos-Tamayo, RafaelMartín-García, AgustínAlarcón-Payer, CarolinaSánchez-Rodríguez, Doloresde la Guardia, Ana María Del Valle DíazGarcía Collado, Carlos GustavoJiménez Morales, AlbertoJurado Chacón, ManuelCabeza Barrera, José2023-02-122023-02-122017-08-22http://hdl.handle.net/10668/19499Multiple myeloma is a very heterogeneous disease with variable survival. Despite recent progress and the widespread use of new agents, patients with relapsed and refractory disease have a poor outcome. Immunomodulatory drugs play a key role in both the front-line and the relapsed/refractory setting. The combination of pomalidomide (POM) and dexamethasone is safe and effective in relapsed and refractory patients, even in those with high-risk cytogenetic features. Furthermore, it can be used in most patients without the need to adjust according to the degree of renal failure. In order to further improve the results, POM-based triplet therapies are currently used. This article highlights the most relevant issues of POM and POM-based combinations in the relapsed/refractory multiple myeloma setting, from a pharmacological and clinical point of view.enAttribution-NonCommercial 4.0 Internationalhttp://creativecommons.org/licenses/by-nc/4.0/dexamethasonemultiple myelomapomalidomidetriplet therapyAntineoplastic Combined Chemotherapy ProtocolsDexamethasoneDrug DesignHumansImmunologic FactorsMultiple MyelomaSurvival RateThalidomideresearch article28860711open access10.2147/DDDT.S1154561177-8881PMC5574598https://www.dovepress.com/getfile.php?fileID=38052https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5574598/pdf